Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis

Overview of attention for article published in BMC Nephrology, January 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (56th percentile)
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

policy: 1 policy source

Citations

dimensions_citation: 16 Dimensions

Readers on

mendeley: 38 Mendeley

Summary Policy documents Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

ravulizumab

Cited by Canadian Agency for Drugs and Technologies in Health on 07 Jun 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.